Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05521698 · ClinicalTrials.gov registry record · Phase 1
A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer
A Phase 1 study, sponsored by University of Wisconsin, Madison.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
NCT05521698 is a Phase 1 study that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 80 participants.
The verdict
NCT05521698, a Phase 1 study, is actively recruiting participants, sponsored by University of Wisconsin, Madison.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
Study Summary
This phase I trial evaluates the effects of bicalutamide, compared to no study drug (NSD), on epidermal growth factor receptor (EGFR) protein expression in patients with non-muscle invasive bladder cancer. Bicalutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of tumor cells. Previous studies have suggested that expression of a protein called EGFR on tumor cells is related to bladder cancer disease progression. This trial may help doctors evaluate if bicalutamide has any effect on EGFR expression in patients with non-muscle invasive bladder cancer.
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Biopsy Procedure
- OTHER Questionnaire Administration
- DRUG Bicalutamide
- PROCEDURE Transurethral Resection of Bladder Tumor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2026-06-25 |
| Est. Completion | 2028-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05521698
The ClinicalTrials.gov registry entry for NCT05521698 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT05521698 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05521698 about?
NCT05521698 is a clinical study titled "A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer". This phase I trial evaluates the effects of bicalutamide, compared to no study drug (NSD), on epidermal growth factor receptor (EGFR) protein expression in patients with non-muscle invasive bladder cancer. Bicalutamide is in a class of medications called androgen receptor inhibitors. It works by blo...
What is the current status of trial NCT05521698?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2026-06-25. Estimated completion is 2028-12-01.
What interventions are being tested in trial NCT05521698?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Biopsy Procedure (PROCEDURE), Questionnaire Administration (OTHER), Bicalutamide (DRUG), Transurethral Resection of Bladder Tumor (PROCEDURE).
Who is sponsoring clinical trial NCT05521698?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.